Patents Represented by Attorney, Agent or Law Firm Douglas A. Golightly
-
Patent number: 8282917Abstract: The present invention provides mutant viruses with a decreased ability to block nuclear transport of mRNA or protein in an infected cell which are attenuated in vivo. The mutant viruses of the present invention may also be capable of triggering the anti-viral systems of normal host cells while remaining sensitive to the effects of these systems. The present invention further provides for the use of the mutant viruses in a range of applications including, but not limited to, as therapeutics for the treatment of cancer and infections, as vaccines and adjuvants, as viral vectors, and as oncolytic and cytolytic agents for the selective lysis of malignant or infected cells.Type: GrantFiled: March 30, 2010Date of Patent: October 9, 2012Assignees: Wellstat Biologics Corporation, Ottawa Hospital Research InstituteInventors: John C. Bell, Brian D. Lichty, David F. Stodjl
-
Patent number: 8236558Abstract: BIV packaging constructs, BIV packaging cell lines, methods of making BIV packaging cells and methods of making BIV producer cells are described.Type: GrantFiled: August 30, 2010Date of Patent: August 7, 2012Assignee: Novartis AGInventors: Tianci Luo, Robert Berkowitz, Michael Kaleko
-
Patent number: 8227440Abstract: The present invention relates to therapeutic use of Myxoma virus. Myxomas virus can selectively infect cells that have a deficient innate anti-viral response, including cells that are not responsive to interferon and can be used to treat diseases characterized by the presence of such cells, including cancer.Type: GrantFiled: August 28, 2009Date of Patent: July 24, 2012Assignee: Robarts Research InstituteInventors: Grant McFadden, John C. Bell
-
Patent number: 8147822Abstract: The present invention is directed to a method of reducing the viability of a tumor cell involving administering a virus that is not a common human pathogen to the tumor cell. Preferably, the virus exhibits differential susceptibility, in that normal cells are not affected by the virus. This differential susceptibility is more pronounced in the presence of interferon. The tumor cell is characterized by having low levels, or no, PKR activity, or as being PKR?/?, STAT1?/? or both PKR?/? and STAT1?/?. The virus is selected from the group consisting of Rhabdovirus and picornavirus, and preferably is vesicular stomatitis virus (VSV) or a derivative thereof.Type: GrantFiled: September 18, 2000Date of Patent: April 3, 2012Assignee: Wellstat Biologics CorporationInventors: John C. Bell, Nahum Sonenberg, David F. Stojdl, Earl G. Brown, Harold L. Atkins, Ricardo M. Marius, Brian D. Lichty, Shane B. Knowles
-
Patent number: 8137663Abstract: A method of treating a human subject with cancer is disclosed. A pharmaceutical composition is administered to the subject, the pharmaceutical composition comprising human leukocytes and a replication-competent oncolytic virus in suspension in a physiologically acceptable solution. Alternatively the pharmaceutical composition comprises human leukocytes or platelets infected with an oncolytic virus.Type: GrantFiled: March 26, 2009Date of Patent: March 20, 2012Assignee: Wellstat Biologics CorporationInventors: William S. Groene, Jeffrey A. Miller, Stephen N. Mueller
-
Patent number: 8105578Abstract: The subject invention relates to viruses that are able to replicate and thereby kill neoplastic cells with a deficiency in the IFN-mediated antiviral response, and their use in treating neoplastic disease including cancer and large tumors. RNA and DNA viruses are useful in this regard. The invention also relates to methods for the selection, design, purification and use of such viruses for cancer therapy.Type: GrantFiled: January 29, 2007Date of Patent: January 31, 2012Assignee: Wellstat Biologics CorporationInventors: Michael S. Roberts, Robert M. Lorence, William S. Groene, Harvey Rabin, Reid W. von Borstel
-
Patent number: 8043612Abstract: The subject invention relates to viruses that are able to replicate and thereby kill neoplastic cells with a deficiency in the IFN-mediated antiviral response, and their use in treating neoplastic disease including cancer and large tumors. RNA and DNA viruses are useful in this regard. The invention also relates to methods for the selection, design, purification and use of such viruses for cancer therapy.Type: GrantFiled: November 18, 2008Date of Patent: October 25, 2011Assignee: Wellstat Biologics CorporationInventors: Michael S. Roberts, Robert M. Lorence, William S. Groene, Harvey Rabin, Reid W. von Borstel
-
Patent number: 7780962Abstract: The subject invention relates to viruses that are able to replicate and thereby kill neoplastic cells with a deficiency in the IFN-mediated antiviral response, and their use in treating neoplastic disease including cancer and large tumors. RNA and DNA viruses are useful in this regard. The invention also relates to methods for the selection, design, purification and use of such viruses for cancer therapy.Type: GrantFiled: June 13, 2002Date of Patent: August 24, 2010Assignee: Wellstat Biologics CorporationInventors: Michael S. Roberts, Robert M. Lorence, William S. Groene, Harvey Rabin, Reid W. von Borstel
-
Patent number: 7767200Abstract: Mammalian subjects having a neoplasm are treated with a virus, a fluoropyrimidine, for example 5-fluorouracil, and a camptothecin compound. The virus is selected from the group consisting of a Newcastle disease virus, a measles virus, a vesicular stomatitis virus, an influenza virus, a Sindbis virus, a picornavirus, and a myxoma virus.Type: GrantFiled: July 12, 2006Date of Patent: August 3, 2010Assignee: Wellstat Biologics CorporationInventors: Robert M. Lorence, Michael S. Roberts
-
Patent number: 7736640Abstract: The invention provides a method of treating cancer in a mammal comprising administering to the mammal an effective amount of virus, particularly Newcastle Disease Virus or other Paramyxovirus. The invention also provides a method of treating cancer in a mammal comprising administering such viruses to the mammal in combination with another agent such as a chemotherapeutic compound, immunoadjuvant, cytokine, or immunosuppressive agent. The invention further provides a method of detecting cancer cells in a mammal using Paramyxovirus as an imaging agent and as an indicator of cancer cell growth in the mammal. The invention further provides genetically engineered Paramyxoviruses, and kits containing the viral compositions disclosed by the invention.Type: GrantFiled: May 26, 2006Date of Patent: June 15, 2010Assignee: Wellstat Biologics CorporationInventors: Robert M. Lorence, Kirk W. Reichard
-
Patent number: 7731974Abstract: The present invention provides mutant viruses with a decreased ability to block nuclear transport of mRNA or protein in an infected cell which are attenuated in vivo. The mutant viruses of the present invention may also be capable of triggering the anti-viral systems of normal host cells while remaining sensitive to the effects of these systems. The present invention further provides for the use of the mutant viruses in a range of applications including, but not limited to, as therapeutics for the treatment of cancer and infections, as vaccines and adjuvants, as viral vectors, and as oncolytic and cytolytic agents for the selective lysis of malignant or infected cells.Type: GrantFiled: March 29, 2004Date of Patent: June 8, 2010Assignees: Ottawa Hospital Research Institute, Wellstat Biologics CorporationInventors: John C. Bell, Brian D. Lichty, David F. Stojdl
-
Patent number: 7595042Abstract: A method of treating a human subject with cancer is disclosed. A pharmaceutical composition is administered to the subject, the pharmaceutical composition comprising human leukocytes and a replication-competent oncolytic virus in suspension in a physiologically acceptable solution. Alternatively the pharmaceutical composition comprises human leukocytes or platelets infected with an oncolytic virus.Type: GrantFiled: May 5, 2005Date of Patent: September 29, 2009Assignee: Wellstat Biologics CorporationInventors: William S. Groene, Jeffrey A. Miller, Stephen N. Mueller
-
Patent number: 7582614Abstract: The present invention relates to therapeutic use of Myxoma virus. Myxoma virus can selectively infect cells that have a deficient innate anti-viral response, including cells that are not responsive to interferon and can be used to treat diseases characterized by the presence of such cells, including cancer.Type: GrantFiled: March 8, 2004Date of Patent: September 1, 2009Assignee: Robarts Research InstituteInventors: Grant McFadden, John C. Bell
-
Patent number: 7217566Abstract: The present invention provides novel cell lines that may have improved adhesive qualities, transgene expression level, growth rate, and/or growth rate in serum free medium or even chemically defined compared to cells of the prior art.Type: GrantFiled: March 22, 2004Date of Patent: May 15, 2007Assignee: Invitrogen CorporationInventors: Sharon Cates, Valentina C. Ciccarone, Dale F. Gruber, Pamela Hawley-Nelson
-
Patent number: 6649375Abstract: An adenoviral vector including at least one DNA sequence encoding a clotting factor, such as, for example, Factor VIII, or Factor IX. Such vectors may be administered to a host in an amount effective to treat hemophilia in the host. The vectors infect hepatocytes very efficiently, whereby the hepatocytes express the DNA sequence encoding the clotting factor.Type: GrantFiled: September 10, 1998Date of Patent: November 18, 2003Assignee: Genetic Theraphy, Inc.Inventors: Sheila Connelly, Michael Kaleko, Theodore Smith
-
Patent number: 6638762Abstract: The invention generally relates to cell-specific expression vectors. It particularly relates to targeted gene therapy using recombinant expression vectors and particularly adenovirus vectors. The invention specifically relates to replication-conditional expression vectors and methods for using them. Such vectors are able to selectively replicate in a target cell or tissue to provide a therapeutic benefit in a tissue from the presence of the vector per se or from one or more heterologous gene products expressed from the vector and distributed throughout the tissue. In such vectors, a gene essential for replication is placed under the control of a heterologous tissue-specific transcriptional regulatory sequence. Thus, replication is conditioned on the presence of a factor(s) that induces transcription or the absence of a factor(s) that inhibits transcription of the gene by means of the transcriptional regulatory sequence with this vector; therefore, a target tissue can be selectively treated.Type: GrantFiled: November 19, 1997Date of Patent: October 28, 2003Assignee: Genetic Therapy, Inc.Inventors: Yung-Nien Chang, Paul L. Hallenbeck, Carl M. Hay, David A. Stewart
-
Patent number: 6620595Abstract: The invention provides novel retroviral vectors that have enhanced transcription termination structures. The termination structures comprise one or several heterologous upstream transcription termination enhancer (UE) sequences, or one or more additional copies of endogenous UE sequences operably associated with the 3′ LTR polyadenylation signal. The retroviral vectors of the invention have various improved properties over conventional vectors, including stronger gene expression, enhanced vector titer and reduced interference with host cell gene expression resulting from read-through of vector initiated transcriptional events.Type: GrantFiled: May 14, 2001Date of Patent: September 16, 2003Assignee: University of Southern CaliforniaInventors: Paula Marie Cannon, Maria Barcova
-
Patent number: 6610534Abstract: A method of inducing blood vessel formation in an animal by administering to the animal a polynucleotide encoding a sphingosine kinase, or an analogue, fragment, or derivative thereof. The polynucleotide may be contained in an appropriate expression vector, such as a viral vector. The delivery of sphingosine kinase through administration of an expression vector which expresses sphingosine kinase provides for the formation of larger blood vessels containing a well defined structure that is supported by mural cells such as pericytes and smooth muscle cells.Type: GrantFiled: October 4, 2001Date of Patent: August 26, 2003Assignee: Novartis AGInventors: Gene Liau, Steingrimur Stefansson, Joseph Su
-
Patent number: 6551587Abstract: The invention generally relates to targeted gene therapy using recombinant vectors and particularly adenovirus vectors. The invention specifically relates to replication-conditional vectors and methods for using them. Such vectors are able to selectively replicate in a target tissue to provide a therapeutic benefit from the presence of the vector per se or from heterologous gene products expressed from the vector and distributed throughout the tissue. In such vectors, a gene essential for replication is placed under the control of a heterologous tissue-specific transcriptional regulatory sequence. Thus, replication is conditioned on the presence of a factor(s) that induces transcription or the absence of a factor(s) that inhibits transcription of the gene by means of the transcriptional regulatory sequence with this vector, therefore, a target tissue can be selectively treated.Type: GrantFiled: December 15, 1998Date of Patent: April 22, 2003Assignee: Genetic Therapy, Inc.Inventors: Paul L. Hallenbeck, Yung-Nien Chang, Yawen L. Chiang
-
Patent number: 6455756Abstract: Immunocompromised mammalian hosts are sub-cutaneously implanted with a combination of human fetal bone and spleen. The chimeric animals can produce human B-cells, myeloid cells and T-cells for up to 9 months in vivo when supplied with an allogeneic human fetal thymic fragment at the same site. Grafts contain cell populations expressing CD4 and CD8, CD19 or CD33, CD14 and CD15, all of which also express the HLA type of the fetal bone/spleen. T-cells derived from progenitors in the fetal bone/spleen contain both mature single positive CD4+CD8−, CD8+CD4− as well as a high percentage of immature double positive CD4+CD8+ populations.Type: GrantFiled: August 12, 1994Date of Patent: September 24, 2002Assignee: Novartis AGInventors: Benjamin P. Chen, Christopher C. Fraser